MicroRNA-106b∼25 expressions in tumor tissues and plasma of patients with gastric cancers

MiR-106b similar to 25 has been researched in several cancers. The aim of this study was to test miR-106b similar to 25 expressions in 40 operative specimens and 20 pre-operative plasma samples of GC patients and explore the correlations between these miRNAs and some related clinical pathological factors. Compared with corresponding adjacent non-tumorous tissues, the expression of miR-106b similar to 25 cluster increased significantly in gastric cancer tissues from 40 samples, with a median relative expression of 2.41(miR-106b), 2.83(miR-93) and 2.71(miR-25). The expression of miRNA-106b similar to 25 cluster in tumor tissues was significantly correlated with tumor size, borrmann type, depth of tumor invasion (T), lymph node metastases (N), distant metastasis (M) and TNM stage (P < 0.05). The expressive level of miRNA-106b similar to 25 cluster was also statistically significant higher than healthy volunteers in plasma, with a median of 2.51(miR-106b), 2.32(miR-93) and 2.10(miR-25). The expression of miR-106b similar to 25 cluster in plasma was significantly correlated with tumor size, borrmann type and TNM stage (P < 0.05) in GC patients. What's more, the three components of miR-106b similar to 25 cluster expressed consistently at a high level both in specimens and plasma. Considering the relationship between three miRNAs and some clinical pathological factors (TNM stage), it was implied that miR-106b similar to 25 could be the next potential tumor biomarker for diagnosis and predictive prognosis for gastric cancer patients.